MUKOVITSIDOZ (KISTALI FIBROZ): ZAMONAVIY TUSHUNCHALAR, DIAGNOSTIKA VA DAVOLASH STRATEGIYALARI

Authors

  • Sobirov Xolmirza Zokirjon o’g’li TDTU 2-son akademik litseyi biologiya fani o’qituvchisi

Keywords:

Mukovitsidoz, kistali fibroz, CFTR geni, avtosomal retsessiv irsiylik, ter testi, bronxial tozalash terapiyasi, CFTR modulyatorlari, o‘pka transplantatsiyasi.

Abstract

Ushbu maqola mukovitsidoz(kistali fibrozning zamonaviy tibbiy tushunchasi, irsiy mexanizmlari, klinik ko‘rinishi, diagnostikasi va kompleks davolash strategiyalariga bag‘ishlangan. Kasallik CFTR genidagi mutatsiyalar natijasida rivojlanadigan, avtosomal retsessiv irsiy kasallik sifatida tavsiflanadi, bu esa organizmdagi ekzokrin bezlarning ishlashini buzib, asosan nafas o‘pka va ovqat hazm qilish tizimiga jiddiy ta’sir etadi. Maqolada kasallikning asosiy klinik ko‘rinishlari (surunkali yo‘tal, respirator infektsiyalar, o‘sishning sekinlashishi), diagnostikaning “oltin standarti” – ter testi (pilokarpinli iontoforez), shuningdek, yangi tug‘ilgan chaqaloqlarni skrining qilish va genetik testlarning ahamiyati chuqur yoritilgan.

Davolash bo‘yicha ko‘p tarmoqli yondashuv, jumladan, nafas yo‘llarini muntazam tozalash fizioterapiyasi, antibiotiklar va mukolitiklardan foydalanish, shuningdek, kasallikning molekulyar sababiga ta’sir qiluvchi yangi davolash sinfi – CFTR modulyatorlari (masalan, ivakaftor) haqida batafsil ma’lumot keltirilgan. Oziqlantirish terapiyasi, ferment preparatlari va o‘pka transplantatsiyasining o‘rni tahli qilinadi.

Maqolada, shuningdek, so‘nggi o‘n yilliklarda tashxis va davolash usullarining yaxshilanishi hisobiga bemorlarning umr ko‘rish davomiyligi va sifatining sezilarli darajada oshgani, ammo davom etayotgan qiyinchiliklar ham ko‘rsatib o‘tilgan. Ishlatilgan manbalar xalqaro ilmiy adabiyotlar (Yevropa va global tadqiqotlar) asosida tanlangan bo‘lib, ularga to‘g‘ri bibliografik ko‘rsatmalar bilan murojaat qilinadi. Ushbu tadqiqot mukovitsidoz bilan og‘rigan bemorlarni boshqarish bo‘yicha tibbiyot amaliyotchilari, rezidentlar va talabalar uchun muhim qo‘llanma sifatida xizmat qilishi mumkin.

References

Elborn, J.S. (2016). Cystic fibrosis. The Lancet, 388(10059), 2519-2531. (Tadqiqot mukovitsidozning hozirgi holati va klinik ko‘rinishini keng qamrovli sharhlaydi).

Farrell, P.M., White, T.B., Ren, C.L., Hempstead, S.E., Accurso, F., Derichs, N., ... & Rosenfeld, M. (2017). Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. The Journal of Pediatrics, 181S, S4-S15.e1. (Kasallikni tashxislash bo‘yicha yangilangan konsensus ko‘rsatmalari).

De Boeck, K., & Amaral, M.D. (2016). Progress in therapies for cystic fibrosis. The Lancet Respiratory Medicine, 4(8), 662-674. (CFTR modulyatorlari kabi zamonaviy davolash usullari haqida chuqur maqola).

Gibson, R.L., Burns, J.L., & Ramsey, B.W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine, 168(8), 918-951. (Mukovitsidozdagi o‘pka infektsiyalarining patofiziologiyasi va boshqaruvi haqida klassik asar).

Sommerburg, O., Hammermann, J., Lindner, M., Stahl, M., Muckenthaler, M., Kohlmueller, D., ... & Mall, M.A. (2015). Five years of experience with biochemical and molecular genetic screening for cystic fibrosis in Germany. Pediatric Pulmonology, 50(7), 655-664. (Germaniyada skrining dasturi natijalari haqida tadqiqot).

Main, E., & Prasad, A. (2021). Physiotherapy in cystic fibrosis: Beyond the traditional. Journal of Cystic Fibrosis, 20, S119-S124. (Fizioterapiyaning zamonaviy usullari va ularning samaradorligi).

European Lung Transplant Registry (ELTR) 2022 Annual Report. (Statistik ma’lumotlar o‘pka transplantatsiyasi natijalari haqida).

Burgel, P.R., Bellis, G., Olesen, H.V., Viviani, L., Zolin, A., Blasi, F., & Elborn, J.S. (2015). Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 46(1), 133-141. (34 ta Yevropa mamlakatida mukovitsidoz demografiyasining kelajakdagi tendentsiyalari haqida tahminlar).

Cutting, G. R. (2022). Cystic fibrosis genetics: From molecular understanding to clinical application. Nature Reviews Genetics, 23(1), 45–59.

O’Sullivan, B. P., & Freedman, S. D. (2020). Cystic fibrosis. Lancet, 395(10241), 1885–1898.

Sermet-Gaudelus, I., et al. (2020). Sweat testing and beyond. Pediatric Pulmonology, 55(11), 3017–3028.

Berkelhammer, C., et al. (2021). Advances in newborn screening. Journal of Cystic Fibrosis, 20(6), 1043–1050.

Ratjen, F., et al. (2022). Cystic fibrosis: Airway disease. Nature Reviews Disease Primers, 8(1), 22.

Shteinberg, M., et al. (2021). Cystic fibrosis. Lancet Respiratory Medicine, 9(4), 377–392.

Middleton, P. G., et al. (2019–2023). Elexacaftor–tezacaftor–ivacaftor therapy. NEJM, 381(19), 1809–1819.

Taylor-Cousar, J. L., et al. (2021). Long-term safety and efficacy of CFTR modulators. AJRCCM, 204(2), 171–182.

Turck, D., et al. (2021). ESPGHAN guidelines for nutrition. JPGN, 72(4), 597–606.

Schwarzenberg, S. J., et al. (2022). Pancreatic disease in cystic fibrosis. Gastroenterology, 162(2), 511–526.

Hayes, D., et al. (2022). Lung transplantation update. JHLT, 41(10), 1347–1360.

ELTR 2023 Report.

Published

2026-01-27

Issue

Section

Articles